<DOC>
	<DOCNO>NCT00375557</DOCNO>
	<brief_summary>The primary aim determine whether Divalproex ER one atypical antipsychotic effective improve dementia related behavioral symptom patient dementia , evaluate impact improvement clinical domain , quality life , functional status .</brief_summary>
	<brief_title>Safety Efficacy Divalproex Quetiapine Elderly Alzheimer 's Dementia Patients</brief_title>
	<detailed_description>This clinical trial open label , flexible dose study Divalproex ER v Quetiapine 6 week . Patients randomize Divalproex ER v Quetiapine outpatient / inpatient . The schedule visit include screen , baseline 3 treatment visit / assessment . The End Study/Early Termination visit conclude Trial . The safety follow-up visit schedule patient unresolved Adverse Events detect prior End Study/Early Termination visit .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Behavioral Symptoms</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>1 . Patients , men woman =/ &gt; 55 year age . 2 . Inpatient / Outpatients diagnosis Moderate Severe probable Alzheimer 's dementia determine Structured Clinical Interview DSMIV . 3 . Patients Mini Mental Status Examination score 315 screening . 4 . Patients Care Giver/ Legal representative Guardian able comprehend satisfactorily comply protocol requirement . 5 . Patient , Care Giver/ Legal representative Guardian sign write informed consent give prior enter study procedure . 6 . Patients least three month ongoing stable dose cholinesterase enzyme inhibitor memantine . 1 . Patients concurrent DSMIV Axis I diagnosis follow category : 1.1 . Delirium , Amnestic Cognitive disorder 1.2 . Lifetime Schizophrenia Psychotic Disorders 1.3 . Lifetime Bipolar I Disorder 1.4 . Bipolar 11 Disorder episode hypomania within last year 1.5 . Alcohol Substance Dependence Abuse ( exclude nicotine ) one month prior Screening Visit 2 . Patients history intolerance hypersensitivity Divalproex ER &amp; Quetiapine . 3 . Patients history seizure . 4 . Patients base history mental status examination significant risk commit suicide . 5 . Patients homicidal violent Investigator 's opinion significant imminent risk hurt others . 6 . Patients treat depotneuroleptic within 3 month prior Baseline Visit . 7 . Patients positive urine drug screen , unless prove prescribed shortterm course treatment . In situation urine drug screen must repeat least 7 day last dose prescription medication contain narcotic . 8 . Patients participate clinical trial within one month prior Screening Visit , clinical trial involve psychotropic medication within 3 month prior Screening Visit . 9 . Patients medical condition , Investigator 's opinion , would expose increase risk significant adverse event interfere assessment safety efficacy course trial . 10 . Patients current malignancy , clinically significant hematological , endocrine , cardiovascular , renal , hepatic , gastrointestinal neurological disease ( include form epilepsy ) . If history disease condition stable least past year judge investigator interfere patient 's participation study , patient may include . 11 . Patients systolic blood pressure great 180 mm Hg le 90 mm Hg diastolic blood pressure great 105 mm Hg le 50 mm Hg Screening visit . 12 . Patients test positive Hepatitis B surface antigen Hepatitis C antibody . 13 . Patients whose laboratory value Screening visit 1.5 time great ULN . 14 . Patients require concomitant treatment psychotropic drug ( except zolpidem sleep 3x/week prn ) . 15 . Patients require concomitant therapy prohibit prescription . 16 . Patients unable speak , read , understand English judge investigator unable unlikely follow study protocol complete schedule visit .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>